Clinical trials: Pyoderma
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
- Trial name
- NCT03137160
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Pyoderma Gangrenosum
Spesolimab in Pyoderma Gangrenosum
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum.
- Trial name
- NCT06092216
- Testing
- Spesolimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
- Trial name
- NCT03971643
- Testing
- vilobelimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
- Trial name
- NCT03072953
- Testing
- APD334
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Arena Pharmaceuticals